No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

byKathleen Lau

February 18, 2021

in StudyGraphics

#VisualAbstract: Enfortumab vedotin prolongs survival in previously treated advanced urothelial carcinoma

RelatedReports

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Oncology

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

June 4, 2026

Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026

#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer

#VisualAbstract: Skin biopsy rates have disproportionately increased compared to cancer treatments between 1993-2016

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Bimekizumab shows better efficacy in treating severe plaque psoriasis than ustekinumab

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports